Skip to Content

Rock Creek Pharmaceuticals Inc RCPIQ

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Rock Creek Pharmaceuticals Inc is engaged in research, development, and commercialization of therapies for chronic inflammatory disease and neurologic disorders, utilizing its proprietary compounds. The company is focusing its drug development efforts on dermatological skin diseases, such as psoriasis, eczema and rare or orphan skin disorders, using its proprietary formulations of its lead compound anatabine citrate. Its objective is to develop, obtain approval for, and commercialize pharmaceutical products utilizing its anatabine-based and related compounds.

Contact
2040 Whitfield Avenue, Suite 300
Sarasota, FL, 34243
T +1 844 727-0727
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Jun 30, 2016
Fiscal Year End Dec 31, 2016
Stock Type Distressed
Employees 5